Table 2

Treatment-related adverse events

All gradeGrade 3–4
Patients with ≥1 events36 (97%)26 (70%)
Fatigue27 (73%)6 (16%)
Fever27 (73%)2 (5%)
Thrombocytopenia25 (68%)4 (11%)
RCCEP23 (62%)0
Nausea23 (62%)5 (14%)
Hypocalcemia23 (62%)0
Amenia22 (59%)2 (5%)
Vomiting20 (54%)4 (11%)
Leukocytopenia19 (51%)4 (11%)
Hyponatremia19 (51%)1 (3%)
Neutropenia18 (49%)5 (14%)
AST increased18 (49%)1 (3%)
Hypoalbuminemia16 (43%)0
Constipation14 (38%)2 (5%)
ALT increased14 (38%)0
Neurotoxicity12 (32%)0
Hypokalemia11 (30%)7 (19%)
Alopecia11 (30%)0
Skin pigmentation10 (27%)0
Diarrhea8 (22%)1 (3%)
ALP increased8 (22%)0
GGT increased8 (22%)5 (14%)
Anorexia7 (19%)0
Peripheral neurotoxicity6 (16%)1 (3%)
Biliary tract infection5 (14%)5 (14%)
Blood bilirubin increased5 (14%)1 (3%)
Hypomagnesemia5 (14%)0
Insomnia5 (14%)0
Parodontopathy5 (14%)0
Hand-foot syndrome4 (11%)0
Hypophosphatemia4 (11%)2 (5%)
Mucositis3 (8%)1 (3%)
Rash3 (8%)2 (5%)
  • Data are n (%) in all treated patients (n=37). The table lists treatment-related adverse events reported in ≥10% patients or grade 3–4 treatment-related adverse events. Patients are counted for each applicable specific adverse event and could have more than one treatment-related event.

  • ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; RCCEP, reactive cutaneous capillary endothelial proliferation.